Template:Acute cystitis antibiotics: Difference between revisions
Ostermayer (talk | contribs) (Marked this version for translation) |
(Convert to AntibioticDose with disease=Acute cystitis) |
||
| Line 6: | Line 6: | ||
<!--T:2--> | <!--T:2--> | ||
'''Women, Uncomplicated''' | '''Women, Uncomplicated''' | ||
* | *{{AntibioticDose|disease=Acute cystitis|drug=Nitrofurantoin|dose=ER 100mg BID x 5d|context=Outpatient, Women Uncomplicated}}, OR | ||
* | *{{AntibioticDose|disease=Acute cystitis|drug=Trimethoprim-Sulfamethoxazole DS|display=TMP/SMX|dose=DS (160/800mg) 1 tab BID x 3d (Females) x7days (Males)|context=Outpatient, Women Uncomplicated}}, OR | ||
* | *{{AntibioticDose|disease=Acute cystitis|drug=Cephalexin|dose=250mg QID x 5d|context=Outpatient, Women Uncomplicated}}, OR | ||
* | *{{AntibioticDose|disease=Acute cystitis|drug=Ciprofloxacin|dose=250mg BID x3d|context=Outpatient, Women Uncomplicated}} | ||
**Avoid using fluoroquinolone for the first-line treatment of uncomplicated urinary tract infections (UTIs) in women.<ref>Choosing Wisely. American Urogynecologic Society. http://www.choosingwisely.org/societies/american-urogynecologic-society</ref> | **Avoid using fluoroquinolone for the first-line treatment of uncomplicated urinary tract infections (UTIs) in women.<ref>Choosing Wisely. American Urogynecologic Society. http://www.choosingwisely.org/societies/american-urogynecologic-society</ref> | ||
* | *{{AntibioticDose|disease=Acute cystitis|drug=Fosfomycin|dose=3 g PO once|context=Outpatient, Women Uncomplicated}} | ||
**Lower clinical and microbiologic success compared to nitrofurantoin TID for 5 days <ref>Huttner, A., Kowalczyk, A., Turjeman, A., Babich, T., Brossier, C., Eliakim-Raz, N., … Harbarth, S. (2018). Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. JAMA: The Journal of the American Medical Association, 319(17), 1781–1789.</ref> | **Lower clinical and microbiologic success compared to nitrofurantoin TID for 5 days <ref>Huttner, A., Kowalczyk, A., Turjeman, A., Babich, T., Brossier, C., Eliakim-Raz, N., … Harbarth, S. (2018). Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. JAMA: The Journal of the American Medical Association, 319(17), 1781–1789.</ref> | ||
'''Women, Complicated''' | '''Women, Complicated''' | ||
* | *{{AntibioticDose|disease=Acute cystitis|drug=Ciprofloxacin|dose=500mg BID x10-14d|context=Outpatient, Women Complicated}}, OR | ||
* | *{{AntibioticDose|disease=Acute cystitis|drug=Cefpodoxime|dose=200 mg BID x10-14d|context=Outpatient, Women Complicated}} | ||
<!--T:3--> | <!--T:3--> | ||
'''Women, Concern for [[Special:MyLanguage/Urethritis|Urethritis]]''' | '''Women, Concern for [[Special:MyLanguage/Urethritis|Urethritis]]''' | ||
* | *{{AntibioticDose|disease=Acute cystitis|drug=Ceftriaxone|dose=250mg IM x1|context=Urethritis Concern}} AND [[azithromycin]] 1gm PO x1 AND [[nitrofurantoin]] ER 100mg BID x5d, OR | ||
* | *{{AntibioticDose|disease=Acute cystitis|drug=Levofloxacin|dose=500mg QD x 14d|context=Urethritis Concern}} (covers urinary pathogens, [[Special:MyLanguage/GC|GC]], and [[Special:MyLanguage/chlamydia|chlamydia]]) | ||
**[[Special:MyLanguage/GC|GC]] resistance to fluoroquinolones is increasing | **[[Special:MyLanguage/GC|GC]] resistance to fluoroquinolones is increasing | ||
<!--T:4--> | <!--T:4--> | ||
'''Men''' | '''Men''' | ||
* | *{{AntibioticDose|disease=Acute cystitis|drug=Ciprofloxacin|dose=500mg BID x10-14d|context=Men}}, OR | ||
* | *{{AntibioticDose|disease=Acute cystitis|drug=Cefpodoxime|dose=200 mg BID x10-14d|context=Men}} | ||
| Line 33: | Line 33: | ||
<!--T:6--> | <!--T:6--> | ||
* | *{{AntibioticDose|disease=Acute cystitis|drug=Ciprofloxacin|dose=400mg IV q12hr|context=Inpatient}}, OR | ||
* | *{{AntibioticDose|disease=Acute cystitis|drug=Ceftriaxone|dose=1gm IV QD|context=Inpatient}}, OR | ||
* | *{{AntibioticDose|disease=Acute cystitis|drug=Cefotaxime|dose=1-2gm IV q8hr|context=Inpatient}}, OR | ||
* | *{{AntibioticDose|disease=Acute cystitis|drug=Gentamicin|dose=3mg/kg/day divided q8hr|context=Inpatient}} +/- ampicillin 1–2 gm q4hr, OR | ||
* | *{{AntibioticDose|disease=Acute cystitis|drug=Piperacillin/Tazobactam|dose=3.375 gm IV q6hr|context=Inpatient}}, OR | ||
* | *{{AntibioticDose|disease=Acute cystitis|drug=Cefepime|dose=2gm IV q8hr|context=Inpatient}}, OR | ||
* | *{{AntibioticDose|disease=Acute cystitis|drug=Imipenem/Cilastatin|dose=500mg IV q8hr|context=Inpatient}} | ||
</translate> | </translate> | ||
Revision as of 23:38, 19 March 2026
Outpatient
Women, Uncomplicated
- Nitrofurantoin ER 100mg BID x 5d, OR
- TMP/SMX DS (160/800mg) 1 tab BID x 3d (Females) x7days (Males), OR
- Cephalexin 250mg QID x 5d, OR
- Ciprofloxacin 250mg BID x3d
- Avoid using fluoroquinolone for the first-line treatment of uncomplicated urinary tract infections (UTIs) in women.[1]
- Fosfomycin 3 g PO once
- Lower clinical and microbiologic success compared to nitrofurantoin TID for 5 days [2]
Women, Complicated
- Ciprofloxacin 500mg BID x10-14d, OR
- Cefpodoxime 200 mg BID x10-14d
Women, Concern for Urethritis
- Ceftriaxone 250mg IM x1 AND azithromycin 1gm PO x1 AND nitrofurantoin ER 100mg BID x5d, OR
- Levofloxacin 500mg QD x 14d (covers urinary pathogens, GC, and chlamydia)
- GC resistance to fluoroquinolones is increasing
Men
- Ciprofloxacin 500mg BID x10-14d, OR
- Cefpodoxime 200 mg BID x10-14d
Inpatient Options
- Ciprofloxacin 400mg IV q12hr, OR
- Ceftriaxone 1gm IV QD, OR
- Cefotaxime 1-2gm IV q8hr, OR
- Gentamicin 3mg/kg/day divided q8hr +/- ampicillin 1–2 gm q4hr, OR
- Piperacillin/Tazobactam 3.375 gm IV q6hr, OR
- Cefepime 2gm IV q8hr, OR
- Imipenem/Cilastatin 500mg IV q8hr
- ↑ Choosing Wisely. American Urogynecologic Society. http://www.choosingwisely.org/societies/american-urogynecologic-society
- ↑ Huttner, A., Kowalczyk, A., Turjeman, A., Babich, T., Brossier, C., Eliakim-Raz, N., … Harbarth, S. (2018). Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. JAMA: The Journal of the American Medical Association, 319(17), 1781–1789.